Immunovant, Inc. Warrants expiring 12/18/2024
IMVTW
IMVTW was delisted on the 15th of June, 2020.
17 hedge funds and large institutions have $20M invested in Immunovant, Inc. Warrants expiring 12/18/2024 in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0% more capital invested
Capital invested by funds: $19.9M → $20M (+$62K)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
6% less funds holding
Funds holding: 18 → 17 (-1)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.25M |
| 2 |
CAC
Cowen and Company
New York
|
+$632K |
| 3 |
SCM
Sio Capital Management
New York
|
+$591K |
| 4 |
ICM
Ionic Capital Management
New York
|
+$520K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$480K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$515K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$473K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$319K |
| 4 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$189K |
| 5 |
AGM
Alpine Global Management
New York
|
-$150K |
IMVTW Hedge Fund Activity: Q1 2020 in Review
17 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Immunovant, Inc. Warrants expiring 12/18/2024 (IMVTW) for Q1 2020, worth a combined $20M — up 0.31% from $19.9M a quarter earlier.
Fund positioning in IMVTW was balanced in Q1 2020: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 6 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $1.25M. The largest seller was Boothbay Fund Management, cutting an estimated $515K.
- 17 institutional investors held Immunovant, Inc. Warrants expiring 12/18/2024 (IMVTW) as of Q1 2020, down from 18 in Q4 2019.
- Funds reported $20M of Immunovant, Inc. Warrants expiring 12/18/2024 stock for Q1 2020, up 0.31% quarter-over-quarter.
- 4 funds opened new Immunovant, Inc. Warrants expiring 12/18/2024 positions in Q1 2020 and 4 closed out, a net change of 0 holders.
- The largest Immunovant, Inc. Warrants expiring 12/18/2024 buyer in Q1 2020 was Eventide Asset Management, an estimated $1.25M added.
- The largest Immunovant, Inc. Warrants expiring 12/18/2024 seller in Q1 2020 was Boothbay Fund Management, an estimated $515K sold.
Based on aggregated 13F filings for Q1 2020.